Theophylline and PDE4 inhibitors in asthma

Current Opinion in Pulmonary Medicine

Volumn 9, Issue 1, 2003, Pages 57-64

  Spina, Domenico ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 [3 (CYCLOPENTYLOXY) 4 METHOXYPHENYL] 2 PHENYLETHYL]PYRIDINE; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; CILOMILAST; ENPROFYLLINE; GLUCOCORTICOID; ISOENZYME; PHOSPHODIESTERASE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PICLAMILAST; ROFLUMILAST; ROLIPRAM; THEOPHYLLINE; UNCLASSIFIED DRUG;

ALLERGIC ASTHMA; ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; CELL ACTIVITY; CELL SURVIVAL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HUMAN; IMMUNOMODULATION; LOW DRUG DOSE; MOLECULAR MECHANICS; NEUTROPHIL; NONHUMAN; PATHOPHYSIOLOGY; RECEPTOR BLOCKING; REVIEW; T LYMPHOCYTE;

ADMINISTRATION, ORAL; ASTHMA; CONTROLLED CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; PHOSPHODIESTERASE INHIBITORS; PROGNOSIS; RESPIRATORY FUNCTION TESTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; THEOPHYLLINE; TREATMENT OUTCOME;

EID: 0037212764     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200301000-00010     Document Type: Review

References (107)

1. Persson CGA, Pauwels R: Pharmacology of antiasthma xanthines. In Pharmacology of Asthma. Edited by Page CP, Barnes PJ. Berlin: Springer-Verlag;1991:207-225.
2. Becker AB, Simons KJ, Gillespie CA, et al.: The bronchodilator effects and pharmacokinetics of caffeine in asthma. N Engl J Med 1984, 310:743-746.
3. Weinberger M, Hendeles L: Theophylline in asthma. N Engl J Med 1996, 334:1380-1388.
4. Ashutosh K, Sedat M, Fragale-Jackson J: Effects of theophylline on respiratory drive in patients with chronic obstructive pulmonary disease. J Clin Pharmacol 1997, 37:1100-1107.
5. Kolbeck RC, Speir WA, Jr., Carrier GO, et al.: Apparent irrelevance of cyclic nucleotides to the relaxation of tracheal smooth muscle induced by theophylline. Lung 1979, 156:173-183.
6. Higbee MD, Kumar M, Galant SP: Stimulation of endogenous catecholamine release by theophylline: A proposed additional mechanism of action for theophylline effects. J Allergy Clin Immunol 1982, 70:377-382.
7. Horrobin DF, Manku MS, Franks DJ, et al.: Methyl xanthine phosphodiesterase inhibitors behave as prostaglandin antagonists in a perfused rat mesenteric artery preparation. Prostaglandins 1977, 13:33-40.
8. Feoktistov I, Biaggioni I: Adenosine A2b receptors evoke interleukin-8 secretion in human mast cells. An enprofylline-sensitive mechanism with implications for asthma. J Clin Invest 1995, 96:1979-1986.
9. Nicholson CD, Shahid M: Inhibitors of cyclic nucleotide phosphodiesteraseisoenzymes - Their potential utility in the therapy of asthma. Pulm Pharmacol 1994, 7:1-17.
10. Ito K, Lim S, Caramori G, et al.: A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci U S A 2002, 99:8921-8926. A recent study providing evidence for a potentially new mechanism to explain the antiinflammatory activity of theophylline. Interestingly, this activity ascribed to theophylline is not shared by PDE4 inhibitors and nor is it mediated via adenosine receptor antagonism. It remains to be established whether drug targeting of this pathway will lead to better antiasthma drugs.
11. Foukas LC, Daniele N, Ktori C, et al.: Direct effects of caffeine and theophylline on the p110d and other phosphoinositiode 3-kinases; Differential effects on lipid kinase and protein kinase activities. J Biol Chem 2002, 277:37124-37130. Another recent study providing an alternative explanation for the antiinflammatory actions attributed to theophylline. Theophylline-inhibited lipid kinase activity of the phosphoinositide (PI) 3-kinase isoforms (recombinant p85α/p110α/p110β/p85α/p100δ and 100γ) and class IA and class II PI-3 kinase activity with IC50 values between 75-800 μmol/L. The phosphorylation of protein kinase (PK) B is one consequence of the activation of PI-3 kinase. Utilizing cell based assays and in vitro tissue preparations, the potency of theophylline against phosphorylation of PKB was found to be between 100-500 μmol/L. It remains to be established whether inhibition of PI-3 kinase accounts for antiinflammatory action of theophylline in asthma, particularly as plasma concentrations often associated with antiinflammatory activity are near or below 10 μg/mL (approximately 30 μmol/L; see [31]).
12. Torphy TJ, Barnette MS, Underwood DC, et al.: Ariflow™ (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: From concept to clinic. Pulm Pharmac Therap 1999, 12:131-135.
13. Schmidt BM, Kusma M, Feuring M, et al.: The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis. J Allergy Clin Immunol 2001, 108:530-536.
14. 1 (approximately 0.4 L; 500 μg dose), morning, and peak expiratory flow (25 mL; 500 μg dose). The drug was safe and well tolerated.
15. Timmer W, Leclerc V, Birraux G, et al.: The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo. J Clin Pharmacol 2002, 42:297-303. Recent study demonstrating the efficacy of a PDE4 inhibitor against exercise-induced asthma. Asthmatic subjects (n = 16) received roflumilast (500 μg per day) for 4 weeks. There was significant bronchoprotection (41%) against exercise after 4 weeks of treatment. This was also accompanied by a reduction in the release of TNF-α from mononuclear cells stimulated with LPS and confirms the view that PDE4 inhibitors demonstrate antiinflammatory activity in man.
16. Finney MJ, Karlsson JA, Persson CG: Effects of bronchoconstrictors and bronchodilators on a novel human small airway preparation. Br J Pharmacol 1985, 85:29-36.
17. Goldie RG, Spina D, Henry PJ, et al.: In vitro responsiveness of human asthmatic bronchus to carbachol, histamine, beta-adrenoceptor agonists and theophylline. Br J Clin Pharmacol 1986, 22:669-676.
18. Cortijo J, Bou J, Beleta J, et al.: Investigation into the role of phosphodiesterase IV in bronchorelaxation, including studies with human bronchus. Br J Pharmacol 1993, 108:562-568.
19. Rabe KF, Tenor H, Dent G, et al.: Phosphodiesterase isozymes modulatinginherent tone in human airways: Identification and characterization. Am J Physiol 1993, 264:L458-L464.
20. Magnussen H, Reuss G, Jorres R: Theophylline has a dose-related effect on the airway response to inhaled histamine and methacholine in asthmatics. Am Rev Respir Dis 1987, 136:1163-1167.
21. Magnussen H, Reuss G, Jorres R: Methylxanthines inhibit exercise-induced bronchoconstriction at low serum theophylline concentration and in a dose-dependent fashion. J Allergy Clin Immunol 1988, 81:531-537.
22. Barlinski J, Lockhart A, Frossard N: Modulation by theophylline and enprofylline of the excitatory non-cholinergic transmission in guinea-pig bronchi. Eur Respir J 1992, 5:1201-1205.
23. Ward AJ, McKenniff M, Evans JM, et al.: Theophylline - An immunomodulatory role in asthma? Am Rev Respir Dis 1993, 147:518-523.
24. Kidney J, Dominguez M, Taylor PM, et al.: Immunomodulation by theophylline in asthma. Demonstration by withdrawal of therapy. Am J Respir Crit Care Med 1995, 151:1907-1914.
25. Pauwels R, van Renterghem D, van der Straeten M, et al.: The effect of theophylline and enprofylline on allergen-induced bronchoconstriction. J Allergy Clin Immunol 1985, 76:583-590.
26. Crescioli S, de Marzo N, Boschetto P, et al.; Theophylline inhibits late asthmatic reactions induced by toluene diisocyanate in sensitised subjects. Eur J Pharmacol 1992, 228:45-50.
27. Hendeles L, Harman E, Huang D, et al.: Theophylline attenuation of airway responses to allergen: Comparison with cromolyn metered-dose inhaler. J Allergy Clin Immunol 1995, 95:505-514.
28. Cockcroft DW, Murdock KY, Gore BP, et al.: Theophylline does not inhibit allergen-induced increase in airway responsiveness to methacholine. J Allergy Clin Immunol 1989, 83:913-920.
29. Mapp C, Boschetto P, dal Vecchio L, et al.: Protective effect of antiasthma drugs on late asthmatic reactions and increased airway responsiveness induced by toluene diisocyanate in sensitized subjects. Am Rev Respir Dis 1987, 136:1403-1407.
30. De Monchy JG, Kauffman HF, Venge P, et al.: Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. Am Rev Respir Dis 1985, 131:373-376.
31. Sullivan P, Bekir S, Jaffar Z, et al.: Antiinflammatory effects of low-dose oral theophylline in atopic asthma [published erratum appears in Lancet 1994; 343:1512]. Lancet 1994, 343:1006-1008. One of the first clinical studies to demonstrate that treatment with doses of theophylline, which achieved plasma levels below those considered to be therapeutic, demonstrated antiinflammatory activity in asthma.
32. Lim S, Tomita K, Carramori G, et al.: Low-dose theophylline reduces eosinophilic inflammation but not exhaled nitric oxide in mild asthma. Am J Respir Crit Care Med 2001, 164:273-276.
33. Aubier M, Neukirch C, Maachi M, et al.: Effect of slow-release theophylline on nasal antigen challenge in subjects with allergic rhinitis. European Respiratory Journal 1998, 11:1105-1110. This clinical study demonstrated that in the upper-respiratory tract, theophylline also demonstrated antiinflammatory activity in allergic rhinitis. The recruitment of eosinophils to the nose was significantly attenuated following treatment with theophylline.
34. Kraft M, Torvik JA, Trudeau JB, et al.: Theophylline: Potential antiinflammatory effects in nocturnal asthma. J Allergy Clin Immunol 1996, 97:1242-1246.
35. D'Alonzo GE, Smolensky MH, Feldman S, et al.: Twenty-four hour lung function in adult patients with asthma. Chronoptimized theophylline therapy once-daily dosing in the evening versus conventional twice-daily dosing. Am Rev Respir Dis 1990, 142:84-90.
36. Nielson CP, Crowley JJ, Morgan ME, et al.: Polymorphonuclear leukocyte inhibition by therapeutic concentrations of theophylline is mediated by cyclic-3′,5′-adenosine monophosphate. Am Rev Respir Dis 1988, 137:25-30.
37. Nielson CP, Crowley JJ, Cusack BJ, et al.: Therapeutic concentrations of theophylline and enprofylline potentiate catecholamine effects and inhibit leukocyte activation. J Allergy Clin Immunol 1986, 78:660-667.
38. Culpitt SV, De Matos C, Russell RE, et al.: Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002, 165:1371-1376. Clinical study demonstrating the ability of theophylline to inhibit the recruitment and activation of inflammatory cells to the lung. Theophylline (150-300 mg twice daily) was administered to subjects with COPD for 4 weeks. The plasma levels achieved with this dosing regime were between 9-11 μg/mL. Theophylline significantly reduced the number of neutrophils recovered from sputum, and the levels of neutrophil granule products including, IL-8, myeloperoxidase, and lactoferrin. Similarly, chemotaxis of neutrophils in response to IL-8 was significantly decreased in subjects who were treated with theophylline. Together, these results illustrate the potential antiinflammatory activity of theophylline in COPD at plasma levels below those considered to be therapeutic.
39. Page CP, Cotter T, Kilfeather S, et al.: Effect of chronic theophylline treatment on the methacholine dose-response curve in allergic asthmatic subjects. European Respiratory Journal 1998, 12:24-29.
40. Bel EH, Timmers MC, Zwinderman AH, et al.: The effect of inhaled corticosteroids on the maximal degree of airway narrowing to methacholine in asthmatic subjects. Am Rev Respir Dis 1991, 143:109-113.
41. Bel EH, Zwinderman AH, Timmers MC, et al.: The protective effect of a beta 2 agonist against excessive airway narrowing in response to bronchoconstrictor stimuli in asthma and chronic obstructive lung disease. Thorax 1991, 46:9-14.
42. Tinkelman DG, Reed CE, Nelson HS, et al.: Aerosol beclomethasone dipropionate compared with theophylline as primary treatment of chronic, mild to moderately severe asthma in children. Pediatrics 1993, 92:64-77.
43. Kelloway JS, Wyatt RA, Adlis SA: Comparison of patients' compliance with prescribed oral and inhaled asthma medications. Arch Intern Med 1994, 154:1349-1352.
44. Barnes PJ, Jonsson B, Klim JB: The costs of asthma. Eur Respir J 1996, 9:636-642.
45. Limatibul S, Shore A, Dosch HM, et al.: Theophylline modulation of E-rosette formation: an indicator of T-cell maturation. Clin Exp Immunol 1978, 33:503-513.
46. Pardi R, Zocchi MR, Ferrero E, et al.: In vivo effects of a single infusion of theophylline on human peripheral blood lymphocytes. Clin Exp Immunol 1984, 57:722-728.
47. Mary D, Aussel C, Ferrua B, et al.: Regulation of interleukin-2 synthesis by cAMP in human T cells. J Immunol 1987, 139:1179-1184.
48. Scordamaglia A, Ciprandi G, Ruffoni S, et al.: Theophylline and the immune response: In vitro and in vivo effects. Clin Immunol Immunopathol 1988, 48:238-246.
49. Shohat B, Volovitz B, Varsano I: Induction of suppressor T cells in asthmatic children by theophylline treatment. Clin Allergy 1983, 13:487-493.
50. Romagnani S: The role of lymphocytes in allergic disease. J Allergy Clin Immunol 2000, 105:399-408.
51. Jaffar ZH, Sullivan P, Page CP et al.: Low-dose theophylline modulates T-lymphocyte activation in allergen-challenged asthmatics. Eur Respir J 1996, 9:456-462. One of many studies that has documented the antilymphocytic activity of theophylline in asthma. The number of lymphocytes and their activity was significantly reduced in bronchial biopsies from individuals treated with low doses of theophylline.
52. Hidi R, Timmermans S, Liu E, et al.: Phosphodiesterase and cyclic adenosine monophosphate-dependent inhibition of T-lymphocyte chemotaxis. Eur Respir J 2000, 15:342-349.
53. Finnerty JP, Lee C, Wilson S, et al.: Effects of theophylline on inflammatory cells and cytokines in asthmatic subjects: A placebo-controlled parallel group study. Eur Respir J 1996, 9:1672-1677. The number of lymphocytes, particularly those generating IL-4 and IL-5 in biopsies was significantly reduced after 6 weeks of treatment with theophylline. This study together with [51] support the view that theophylline documents antilymphocytic activity in asthma.
54. Kosmas EN, Michaelides SA, Polychronaki A, et al.: Theophylline induces a reduction in circulating interleukin-4 and interleukin-5 in atopic asthmatics [In Process Citation]. Eur Respir J 1999, 13:53-58.
55. Mascali JJ, Cvietusa P, Negri J, et al.: Antiinflammatory effects of theophylline: Modulation of cytokine production. Ann Allergy Asthma Immunol 1996, 77:34-38.
56. Punnonen J, Punnonen K, Jansen CT, et al.: Interferon (IFN)-alpha, IFN-gamma, interleukin (IL)-2, and arachidonic acid metabolites modulate IL-4- induced IgE synthesis similarly in healthy persons and in atopic dermatitis patients. Allergy 1993, 48:189-195.
57. Enk AH, Angeloni VL, Udey MC, et al.: Inhibition of Langerhans cell antigen-presenting function by IL-10. A role for IL-10 in induction of tolerance. J Immunol 1993, 151:2390-2398.
58. Yoshida N, Shimizu Y, Kitaichi K, et al.: Differential effect of phosphodiesterase inhibitors on IL-13 release from peripheral blood mononuclear cells. Clin Exp Immunol 2001, 126:384-389.
59. Fink G, Mittelman M, Shohat B, et al.: Theophylline-induced alterations in cellular immunity in asthmatic patients. Clin Allergy 1987, 17:313-316.
60. Guillou PJ, Ramsden C, Kerr M, et al.: A prospective controlled clinical trial of aminophylline as an adjunctive immunosuppressive agent. Transplant Proc 1984, 16:1218-1220.
61. Ohta K, Yamashita N: Apoptosis of eosinophils and lymphocytes in allergic inflammation. J Allergy Clin Immunol 1999, 104:14-21.
62. Yasui K, Hu B, Nakazawa T, et al.: Theophylline accelerates human granulocyte apoptosis not via phosphodiesterase inhibition. Journal of Clinical Investigation 1997, 100:1677-1684. One of the first studies to propose that apoptosis of human eosinophils in vitro is not mimicked by PDE4 inhibition. Hence, it might be inferred that the antiinflammatory activity attributed to theophylline is mediated by mechanisms other than PDE4 inhibition. Whilst this mechanism was not investigated in this study, recent reports of a novel mechanism [10•] may need be evaluated in this model.
63. Takeuchi M, Tatsumi Y, Kitaichi K, et al.: Selective phosphodiesterase type 4 inhibitors reduce the prolonged survival of eosinophils stimulated by granulocyte-macrophage colony-stimulating factor. Biol Pharm Bull 2002, 25:184-187.
64. Banner KH, Hoult JR, Taylor MN, et al.: Possible contribution of prostaglandin E2 to the antiproliferative effect of phosphodiesterase 4 inhibitors in human mononuclear cells. Biochem Pharmacol 1999, 58:1487-1495. Another study that demonstrates that theophylline and PDE4 inhibitors behave different in cell based assays and suggest that the antiinflammatory activity of theophylline in vivo may not be mediated via inhibition of PDE4.
65. Peterson TC, Slysz G, Isbrucker R: The inhibitory effect of ursodeoxycholic acid and pentoxifylline on platelet derived growth factor-stimulated proliferation is distinct from an effect by cyclic AMP. Immunopharmacology 1998, 39:181-191.
66. Persson CG, Pauwels R: Pharmacology of antiasthma xanthines. In Pharmacology of Asthma. Edited by Page CP, Barnes PJ. London: Academic Press; 1989:207-225.
67. Feoktistov I, Polosa R, Holgate ST, et al.: Adenosine A2B receptors: A novel therapeutic target in asthma? Trends Pharmacol Sci 1998, 19:148-153.
68. Cushley MJ, Tattersfield AE, Holgate ST: Inhaled adenosine and guanosine on airway resistance in normal and asthmatic subjects. Br J Clin Pharmacol 1983, 15:161-165.
69. Cushley MJ, Tattersfield AE, Holgate ST: Adenosine-induced bronchoconstriction in asthma. Antagonism by inhaled theophylline. Am Rev Respir Dis 1984, 129:380-384.
70. Mann JS, Holgate ST: Specific antagonism of adenosine-induced bronchoconstriction in asthma by oral theophylline. Br J Clin Pharmacol 1985, 19:685-692.
71. El Hashim A, D'Agostino B, Matera MG, et al.: Characterization of adenosine receptors involved in adenosine-induced bronchoconstriction in allergic rabbits. Br J Pharmacol 1996, 119:1262-1268.
72. Nyce JW, Metzger WJ: DNA antisense therapy for asthma in an animal model. Nature 1997, 385:721-725.
73. Bjorck T, Gustafsson LE, Dahlen SE: Isolated bronchi from asthmatics are hyperresponsive to adenosine, which apparently acts indirectly by liberation of leukotrienes and histamine. Am Rev Respir Dis 1992, 145:1087-1091.
74. Yasui K, Agematsu K, Shinozaki K, et al.: Theophylline induces neutrophil apoptosis through adenosine A2A receptor antagonism. J Leukoc Biol 2000, 67:529-535.
75. Ezeamuzie CI: Involvement of A(3) receptors in the potentiation by adenosine of the inhibitory effect of theophylline on human eosinophil degranulation: Possible novel mechanism of the antiinflammatory action of theophylline. Biochem Pharmacol 2001, 61:1551-1559.
76. Landells LJ, Szilagy CM, Jones NA, et al.: Identification and quantification of phosphodiesterase 4 subtypes in CD4 and CD8 lymphocytes from healthy and asthmatic subjects. Br J Pharmacol 2001, 133:722-729.
77. Evans DJ, Taylor DA, Zetterstrom O, et al.: A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med 1997, 337:1412-1418.
78. Ukena D, Harnest U, Sakalauskas R, et al.: Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma. Eur Respir J 1997, 10:2754-2760.
79. Brenner M, Berkowitz R, Marshall N, et al.: Need for theophylline in severe steroid-requiring asthmatics. Clin Allergy 1988, 18:143-150.
80. Rivington RN, Boulet LP, Cote J, et al.: Efficacy of Uniphyl, salbutamol, and their combination in asthmatic patients on high-dose inhaled steroids. Am J Respir Crit Care Med 1995, 151:325-332.
81. Torphy TJ: Phosphodiesterase isozymes: Molecular targets for novel anti-asthma agents. Am J Respir Crit Care Med 1998, 157:351-370.
82. Essayan DM: Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol 2001, 108:671-680.
83. Souness JE, Aldous D, Sargent C: Immunosuppressive and antiinflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology 2000, 47:127-162.
84. Essayan DM, Huang SK, Undem BJ, et al.: Modulation of antigen- and mitogen-induced proliferative responses of peripheral blood mononuclear cells by nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors. J Immunol 1994, 153:3408-3416.
85. Essayan DM, Kagey-Sobotka A, Lichtenstein LM, et al.: Differential regulation of human antigen-specific Th1 and Th2 lymphocyte responses by isozyme selective cyclic nucleotide phosphodiesterase inhibitors. Journal of Pharmacology & Experimental Therapeutics 1997, 282:505-512.
86. Crocker IC, Townley RG, Khan MM: Phosphodiesterase inhibitors suppress proliferation of peripheral blood mononuclear cells and interleukin-4 and -5 secretion by human T-helper type 2 cells. Immunopharmacology 1996, 31:223-235.
87. Bielekova B, Lincoln A, McFarland H, et al.: Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1-mediated autoimmune diseases. J Immunol 2000, 164:1117-1124.
88. + T-lymphocytes and macrophages in patients with chronic obstructive pulmonary disease (COPD): A double-blind placebo-controlled, parallel-group quantitative study of bronchial biopsies [abstract]. Eur Respir J 2001, 17:2238.
89. Spina D, Landells LJ, Page CP: The role of phosphodiesterase isoenzymes in health and in atopic disease. In Advances in Pharmacology. Edited by August T. San Diego: Academic Press Inc; 1998:33-89.
90. Underwood DC, Bochnowicz S, Osborn RR, et al.: Antiasthmatic activity of the second-generation phosphodiesterase 4 (PDE4) inhibitor SB 207499 (Ariflo) in the guinea pig. J Pharmacol Exp Ther 1998, 287:988-995.
91. Bundschuh DS, Eltze M, Barsig J, et al.: In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther 2001, 297:280-290.
92. Harbinson PL, MacLeod D, Hawksworth R, et al.: The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects. Eur Respir J 1997, 10:1008-1014.
93. Jonker GJ, Tijhuis GJ, de Monchey JGR: RP 73401 (a phosphodiesterase IV inhibitor) single does not prevent allergen induced bronchoconstriction during the early phase reaction in asthmatics, Eur Respir J 1996, 9:82s.
94. Nell H, Louw C, Leichtl S, et al.: Acute antiinflammatory effect of the novel phosphodiesterase 4 inhibitor roflumilast on allergen challenge in asthmatics after a single dose [abstract]. Am J Respir Crit Care Med 2000, 161:A200.
95. Weston MC, Anderson N, Peachell PT: Effects of phosphodiesterase inhibitors on human lung mast cell and basophil function. Br J Pharmacol 1997, 121:287-295.
96. Schmidt DT, Watson N, Dent G, et al.: The effect of selective and nonselective phosphodiesterase inhibitors on allergen- and leukotriene C(4)-induced contractions in passively sensitized human airways. Br J Pharmacol 2000, 131:1607-1618.
97. Myou S, Fujimura M, Kamio Y, et al.: Bronchodilator effect of inhaled Olprinone, a phosphodiesterase 3 inhibitor, in asthmatic patients. Am J Respir Crit Care Med 1999, 160;817-820.
98. Nieman RB, Fisher BD, Amit O, Dockhorn RJ: SB 207499 (Ariflow™), a second-generation, selective oral phosphodiesterase type 4 (PDE4) inhibitor, attenuates exercise induced bronchoconstriction in patients with asthma [abstract]. Am J Respir Crit Care Med 1998, 157:A413.
99. Leichtl S, Syed J, Bredenbroker D, et al.: Efficacy of once-daily roflumilast, a new orally active, selective phosphodiesterase4 inhibitor, in chronic obstructive pulmonary disease [abstract]. Am J Respir Crit Care Med 2002, 165:A229.
100. Compton CH, Gubb J, Nieman R, et al.: Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: A randomised, dose-ranging study. Lancet 2001, 358:265-270.
101. Qian Y, Girard V, Martin CA, et al.: Rolipram, but not siguazodan or zaprinast, inhibits the excitatory noncholinergic neurotransmission in guinea-pig bronchi. Eur Respir J 1994, 7:306-310.
102. Undem BJ, Meeker SN, Chen J: Inhibition of neurally mediated nonadrenergic, noncholinergic contractions of guinea pig bronchus by isozyme-selective phosphodiesterase inhibitors. J Pharmacol Exp Ther 1994, 271:811-817.
103. Spina D, Harrison S, Page CP: Regulation by phosphodiesterase isoenzymes of non-adrenergic non-cholinergic contraction in guinea-pig isolated main bronchus. Br J Pharmacol 1995, 116:2334-2340.
104. Holbrook M, Gozzard N, James T, et al.: Inhibition of bronchospasm and ozone-induced airway hyperresponsiveness in the guinea-pig by CDP840, a novel phosphodiesterase type 4 inhibitor. Br J Pharmacol 1996, 118:1192-1200.
105. Juilfs DM, Fulle HJ, Zhao AZ, et al.: A subset of olfactory neurons that selectively express cGMP-stimulated phosphodiesterase (PDE2) and guanylyl cyclase-D define a unique olfactory signal transduction pathway. Proc Natl Acad Sci U S A 1997, 94:3388-3395.
106. Lamontagne S, Meadows E, Luk P, et al.: Localization of phosphodiesterase-4 isoforms in the medulla and nodose ganglion of the squirrel monkey. Brain Res 2001, 920:84-96.
107. Hunter DD, Myers AC, Undem BJ: Nerve growth factor-induced phenotypic switch in guinea pig airway sensory neurons, Am J Respir Crit Care Med 2000, 161:1985-1990.